Abstract
In a multicentre trial of the EORTC-Early Clinical Trials Group (ECTG) we treated 31 chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) with rhizoxin, a novel tubulin-binding agent. The drug was given as an i.v. bolus injection at 2 mg m-2 once every 3 weeks in an outpatient setting. Prophylactic antiemetics were not routinely given. Of the 29 eligible patients, nine had been treated surgically and three had received radiotherapy. The main toxic effects observed were stomatitis (34% of cycles) and neutropenia (41% of cycles). Neutropenic fever was rare (3% of cycles). Twenty-seven patients were evaluable for response. There were four partial responses (15%), while 13 patients (48%) showed stabilisation of their disease. The median duration of response was 7 months (range 6.0-10.7 months) and median survival from the start of rhizoxin treatment was 6 months (range 2-14.7 months). Rhizoxin as single agent shows activity in patients with advanced NSCLC.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bakowski M. T., Crouch J. C. Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. Cancer Treat Rev. 1983 Sep;10(3):159–172. doi: 10.1016/0305-7372(83)90030-0. [DOI] [PubMed] [Google Scholar]
- Bissett D., Graham M. A., Setanoians A., Chadwick G. A., Wilson P., Koier I., Henrar R., Schwartsmann G., Cassidy J., Kaye S. B. Phase I and pharmacokinetic study of rhizoxin. Cancer Res. 1992 May 15;52(10):2894–2898. [PubMed] [Google Scholar]
- Bonomi P. D., Finkelstein D. M., Ruckdeschel J. C., Blum R. H., Green M. D., Mason B., Hahn R., Tormey D. C., Harris J., Comis R. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1989 Nov;7(11):1602–1613. doi: 10.1200/JCO.1989.7.11.1602. [DOI] [PubMed] [Google Scholar]
- Cerny T., Kaplan S., Pavlidis N., Schöffski P., Epelbaum R., van Meerbeek J., Wanders J., Franklin H. R., Kaye S. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG) Br J Cancer. 1994 Aug;70(2):384–387. doi: 10.1038/bjc.1994.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hendriks H. R., Plowman J., Berger D. P., Paull K. D., Fiebig H. H., Fodstad O., Dreef-van der Meulen H. C., Henrar R. E., Pinedo H. M., Schwartsmann G. Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent. Ann Oncol. 1992 Nov;3(9):755–763. doi: 10.1093/oxfordjournals.annonc.a058334. [DOI] [PubMed] [Google Scholar]
- Joss R. A., Cavalli F., Goldhirsch A., Mermillod B., Brunner K. W. New agents in non-small cell lung cancer. Cancer Treat Rev. 1984 Sep;11(3):205–236. doi: 10.1016/0305-7372(84)90009-4. [DOI] [PubMed] [Google Scholar]
- Rapp E., Pater J. L., Willan A., Cormier Y., Murray N., Evans W. K., Hodson D. I., Clark D. A., Feld R., Arnold A. M. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol. 1988 Apr;6(4):633–641. doi: 10.1200/JCO.1988.6.4.633. [DOI] [PubMed] [Google Scholar]
- Thomas P., Rubinstein L. Cancer recurrence after resection: T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1990 Feb;49(2):242–247. doi: 10.1016/0003-4975(90)90145-v. [DOI] [PubMed] [Google Scholar]
- Tsuruo T., Oh-hara T., Iida H., Tsukagoshi S., Sato Z., Matsuda I., Iwasaki S., Okuda S., Shimizu F., Sasagawa K. Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines. Cancer Res. 1986 Jan;46(1):381–385. [PubMed] [Google Scholar]